International Oncology Network - Cancer & Hematology News

Peter Hofland, PhD's Blog – April 2010 Archive (7)

Sipuleucel-T Approved for the Treatment of Men with Advanced Prostate Cancer

Sipuleucel-T (PROVENGE®, Dendreon Corporation), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC) has been approved by the FDA for the treatment of men with advanced prostate cancer in the US. Sipuleucel-T is designed to induce an immune response against… Continue

Added by Peter Hofland, PhD on April 29, 2010 at 11:00am — No Comments

Challenges and Opportunities of Developing a Cancer Survivorship Program

Cancer patients who have completed treatment would be better served if oncology treatment centers were equipped to offer them comprehensive, pro-active follow-up care, according to experts who presented at the survivorship forum 'Developing a Cancer Survivorship Program' being held in Atlanta (Wednesday April 28, 2010).

"Earlier detection and better treatment methods mean that two of every three adult cancer survivors are living five years after…

Continue

Added by Peter Hofland, PhD on April 29, 2010 at 5:00am — No Comments

Research Demonstrates Excellent Results for IORT Treatment Using Electronic Brachytherapy

The use of electronic brachytherapy systems to deliver intraoperative radiation therapy (IORT) is growing as clinical experience demonstrates the isotope-free cancer treatment platform is a patient and physician friendly alternative. This is one of the conclusions presented to breast cancer surgeons during the 11th Annual Meeting of the American Society of Breast Surgeons in las Vegas, NV, April 28-May 2, 2010.

The conclusion is based on the results from…

Continue

Added by Peter Hofland, PhD on April 28, 2010 at 5:00pm — No Comments

New Phase II Study planned for Brostallicin, a Novel Targeted Approach in the Treatment of mTNBC

The North Central Cancer Treatment Group (NCCTG), a national clinical research group sponsored by the National Cancer Institute, plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast (mTNBC) cancer. These cancers…

Continue

Added by Peter Hofland, PhD on April 27, 2010 at 11:00pm — No Comments

New Dutch Biotechnology Company Secures Funding to Develop Novel Oncology Therapeutics

Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and LUPUS Ventures BV. Immunovo combines the most desirable features of synthetic immunogen development with the recent insights into mechanisms driving tumor growth and metastasis, to create highly specific and powerful in vivo therapeutic immune responses.…

Continue

Added by Peter Hofland, PhD on April 27, 2010 at 11:00am — No Comments

EMEA Recommends Expanded Pediatric Investigation Plan for Pixantrone

The European Medicines Agency (EMEA) Pediatric Committee (PDCO) today released its findings requested that Cell Therapeutics, Inc submit an updated Pediatric Investigation Plan (PIP) for pixantrone following discussions about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer.

Following the request Cell Therapeutics, cexpects to…

Continue

Added by Peter Hofland, PhD on April 21, 2010 at 7:00pm — No Comments

Interim Phase I/II Results Shows that Systemic and Antigen-Specific Immune Responses in Patients Treated with Cancer Vaccine BPX-101 Correlate with Clinical Response

The interim Phase I/II efficacy data for BPX-101 (Bellicum Pharmaceuticals, Inc.), a novel dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in a Late Breaking poster at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 held in Washington, D.C. shows systemic and antigen-specific immune responses correlating with clinical response.

Guru Sonpavde,… Continue

Added by Peter Hofland, PhD on April 19, 2010 at 1:00pm — No Comments